Avamab (Bevacizumab) 400 mg/16 mL Concentrate for Solution for Infusion

Manufacturer
GH Genhelix S.A.(SPAIN)

Registraction Number
MAL24066006ACZ

Content:

• Active Ingredient: Bevacizumab 400 mg per 16 mL

• Metastatic colorectal cancer: In combination with fluorouracil-based chemotherapy.
• Non-squamous non-small cell lung cancer: In combination with carboplatin and paclitaxel.
• Metastatic breast cancer: In combination with paclitaxel.
• Glioblastoma: As a single agent for patients with progressive disease following prior therapy.
• Renal cell carcinoma: In combination with interferon alfa-2a.
• Cervical cancer: In combination with paclitaxel plus cisplatin or topotecan.
• Ovarian, Fallopian Tube, or Peritoneal Cancer: In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan.

• Metastatic colorectal cancer: 5 mg/kg IV every 2 weeks with bolus-IFL (irinotecan, 5-FU, leucovorin) or 10 mg/kg IV every 2 weeks with FOLFOX4 (oxaliplatin, 5-FU, leucovorin).
• Non-small cell lung cancer: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel.
• Metastatic breast cancer: 15 mg/kg IV every 3 weeks with paclitaxel.
• Glioblastoma: 10 mg/kg IV every 2 weeks.
• Renal cell carcinoma: 10 mg/kg IV every 2 weeks.
• Cervical cancer: 15 mg/kg IV every 3 weeks with paclitaxel and cisplatin or paclitaxel and topotecan.
• Ovarian, Fallopian Tube, or Peritoneal Cancer: 10 mg/kg IV every 2 weeks or 15 mg/kg IV every 3 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan.